Topics

Multi-study data confirms Ocrevus' long-term efficacy in reducing disability progression in multiple sclerosis

06:09 EDT 13 Sep 2019 | Pharmafile

Roche has taken the opportunity at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Stockholm to reveal new longer-term data from three Phase 3 trials demonstrating that the ability of Ocrevus (ocrelizumab) to reduce the risk of disability progression in multiple sclerosis (MS) patients was sustained over a period of years

It was shown that continuous treatment with Ocrevus for six years or more led to reduced risk of disability progression in relapsing MS (RMS) and primary progressive MS (PPMS).

read more

Original Article: Multi-study data confirms Ocrevus' long-term efficacy in reducing disability progression in multiple sclerosis

NEXT ARTICLE

More From BioPortfolio on "Multi-study data confirms Ocrevus' long-term efficacy in reducing disability progression in multiple sclerosis"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...